{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:36:42Z","timestamp":1793313402201,"version":"4.5.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,5,22]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>Loss of ATR signaling is cytotoxic to AML cells in combination with gemcitabine and hydroxyurea via the induction of replication stress. A small molecule inhibitor of ATR in combination with gemcitabine completely eradicates AML in an orthotopic xenograft mouse model.<\/jats:p>","DOI":"10.1182\/bloodadvances.2017015214","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T12:30:16Z","timestamp":1526992216000},"page":"1157-1169","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":45,"title":["Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase"],"prefix":"10.1182","volume":"2","author":[{"given":"Sarah E.","family":"Fordham","sequence":"first","affiliation":[{"name":"Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen J.","family":"Blair","sequence":"additional","affiliation":[{"name":"Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire J.","family":"Elstob","sequence":"additional","affiliation":[{"name":"Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[{"name":"Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Drew","sequence":"additional","affiliation":[{"name":"Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola J.","family":"Curtin","sequence":"additional","affiliation":[{"name":"Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Heidenreich","sequence":"additional","affiliation":[{"name":"Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Pal","sequence":"additional","affiliation":[{"name":"Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jamieson","sequence":"additional","affiliation":[{"name":"Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Park","sequence":"additional","affiliation":[{"name":"Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Pollard","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals (Europe) Ltd, Abingdon, Oxfordshire, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Fields","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals (Europe) Ltd, Abingdon, Oxfordshire, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Milne","sequence":"additional","affiliation":[{"name":"Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham H.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Department of Haematology, Freeman Hospital, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen J.","family":"Marr","sequence":"additional","affiliation":[{"name":"Department of Haematology, Freeman Hospital, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Menne","sequence":"additional","affiliation":[{"name":"Department of Haematology, Freeman Hospital, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail L.","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Haematology, Freeman Hospital, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Allan","sequence":"additional","affiliation":[{"name":"Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,5,22]]},"reference":[{"issue":"5","key":"2019111616020841700_B1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrc3916","article-title":"Replication stress and cancer","volume":"15","author":"Gaillard","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"5625","key":"2019111616020841700_B2","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1126\/science.1083430","article-title":"Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes","volume":"300","author":"Zou","year":"2003","journal-title":"Science"},{"issue":"1","key":"2019111616020841700_B3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/ncb1337","article-title":"ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks","volume":"8","author":"Jazayeri","year":"2006","journal-title":"Nat Cell Biol"},{"issue":"5","key":"2019111616020841700_B4","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","article-title":"ATR prohibits replication catastrophe by preventing global exhaustion of RPA","volume":"155","author":"Toledo","year":"2013","journal-title":"Cell"},{"issue":"14","key":"2019111616020841700_B5","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1101\/gad.214080.113","article-title":"ATR phosphorylates SMARCAL1 to prevent replication fork collapse","volume":"27","author":"Couch","year":"2013","journal-title":"Genes Dev"},{"issue":"6","key":"2019111616020841700_B6","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.molcel.2015.07.029","article-title":"Distinct but concerted roles of ATR, DNA-PK, and Chk1 in countering replication stress during S phase","volume":"59","author":"Buisson","year":"2015","journal-title":"Mol Cell"},{"key":"2019111616020841700_B7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canep.2016.03.011","article-title":"Myeloid malignancies in the real-world: occurrence, progression and survival in the UK\u2019s population-based Haematological Malignancy Research Network 2004-15","volume":"42","author":"Roman","year":"2016","journal-title":"Cancer Epidemiol"},{"issue":"5868","key":"2019111616020841700_B8","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1126\/science.1140735","article-title":"An oncogene-induced DNA damage model for cancer development","volume":"319","author":"Halazonetis","year":"2008","journal-title":"Science"},{"issue":"3","key":"2019111616020841700_B9","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.molonc.2014.11.001","article-title":"Myc and Ras oncogenes engage different energy metabolism programs and evoke distinct patterns of oxidative and DNA replication stress","volume":"9","author":"Maya-Mendoza","year":"2015","journal-title":"Mol Oncol"},{"issue":"6","key":"2019111616020841700_B10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nrd4553","article-title":"Exploiting replicative stress to treat cancer","volume":"14","author":"Dobbelstein","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"5667","key":"2019111616020841700_B11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.1093933","article-title":"Development of a human adaptive immune system in cord blood cell-transplanted mice","volume":"304","author":"Traggiai","year":"2004","journal-title":"Science"},{"key":"2019111616020841700_B12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"issue":"1","key":"2019111616020841700_B13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jmb.2010.07.010","article-title":"Methylated DNA causes a physical block to replication forks independently of damage signalling, O(6)-methylguanine or DNA single-strand breaks and results in DNA damage","volume":"402","author":"Groth","year":"2010","journal-title":"J Mol Biol"},{"issue":"3","key":"2019111616020841700_B14","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bjc.2011.243","article-title":"Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines","volume":"105","author":"Peasland","year":"2011","journal-title":"Br J Cancer"},{"issue":"1","key":"2019111616020841700_B15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat Cell Biol"},{"issue":"16","key":"2019111616020841700_B16","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/onc.2014.155","article-title":"Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies","volume":"34","author":"Aye","year":"2015","journal-title":"Oncogene"},{"issue":"11","key":"2019111616020841700_B17","doi-asserted-by":"crossref","DOI":"10.3390\/genes7110099","article-title":"The cell killing mechanisms of hydroxyurea","volume":"7","author":"Singh","year":"2016","journal-title":"Genes (Basel)"},{"issue":"1","key":"2019111616020841700_B18","doi-asserted-by":"crossref","first-page":"37250","DOI":"10.1038\/srep37250","article-title":"Profiling ribonucleotide and deoxyribonucleotide pools perturbed by gemcitabine in human non-small cell lung cancer cells","volume":"6","author":"Guo","year":"2016","journal-title":"Sci Rep"},{"key":"2019111616020841700_B19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"1-2","key":"2019111616020841700_B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1570-9639(04)00054-8","article-title":"Structure, function, and mechanism of ribonucleotide reductases","volume":"1699","author":"Kolberg","year":"2004","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"2019111616020841700_B21","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.3892\/or.2017.5580","article-title":"Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine","volume":"37","author":"Liu","year":"2017","journal-title":"Oncol Rep"},{"issue":"12","key":"2019111616020841700_B22","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/cddis.2012.181","article-title":"Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation","volume":"3","author":"Fokas","year":"2012","journal-title":"Cell Death Dis"},{"issue":"12","key":"2019111616020841700_B23","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/nsmb.2189","article-title":"Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors","volume":"18","author":"Murga","year":"2011","journal-title":"Nat Struct Mol Biol"},{"issue":"22","key":"2019111616020841700_B24","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.1158\/1078-0432.CCR-11-1198","article-title":"Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells","volume":"17","author":"H\u00f6glund","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2019111616020841700_B25","doi-asserted-by":"crossref","first-page":"13837","DOI":"10.1038\/ncomms13837","article-title":"ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A","volume":"7","author":"Williamson","year":"2016","journal-title":"Nat Commun"},{"issue":"445","key":"2019111616020841700_B26","doi-asserted-by":"crossref","first-page":"ra91","DOI":"10.1126\/scisignal.aad8243","article-title":"Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML","volume":"9","author":"Morgado-Palacin","year":"2016","journal-title":"Sci Signal"},{"issue":"23","key":"2019111616020841700_B27","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.1158\/0008-5472.CAN-13-3369","article-title":"ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses","volume":"74","author":"Joss\u00e9","year":"2014","journal-title":"Cancer Res"},{"issue":"11","key":"2019111616020841700_B28","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.4161\/cbt.21093","article-title":"The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy","volume":"13","author":"Prevo","year":"2012","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"2019111616020841700_B29","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0026-895X(25)09518-5","article-title":"Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2\u2032,2\u2032-difluorodeoxycytidine","volume":"38","author":"Heinemann","year":"1990","journal-title":"Mol Pharmacol"},{"issue":"1","key":"2019111616020841700_B30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41467-017-00221-3","article-title":"ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways","volume":"8","author":"Le","year":"2017","journal-title":"Nat Commun"},{"issue":"3","key":"2019111616020841700_B31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20131738","article-title":"Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication","volume":"211","author":"Nathanson","year":"2014","journal-title":"J Exp Med"},{"issue":"5","key":"2019111616020841700_B32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ccell.2015.09.015","article-title":"Inhibiting wee1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation","volume":"28","author":"Pfister","year":"2015","journal-title":"Cancer Cell"},{"issue":"3","key":"2019111616020841700_B33","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.cell.2011.03.044","article-title":"Nucleotide deficiency promotes genomic instability in early stages of cancer development","volume":"145","author":"Bester","year":"2011","journal-title":"Cell"},{"issue":"24","key":"2019111616020841700_B34","doi-asserted-by":"crossref","first-page":"9815","DOI":"10.1073\/pnas.1013274108","article-title":"Clofarabine 5\u2032-di and -triphosphates inhibit human ribonucleotide reductase by altering the quaternary structure of its large subunit","volume":"108","author":"Aye","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2019111616020841700_B35","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0026-895X(25)14620-8","article-title":"In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells","volume":"21","author":"Tseng","year":"1982","journal-title":"Mol Pharmacol"},{"issue":"9","key":"2019111616020841700_B36","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0021-9258(18)96025-4","article-title":"Effects of arabinonucleotides on ribonucleotide reduction by an enzyme system from rat tumor","volume":"242","author":"Moore","year":"1967","journal-title":"J Biol Chem"},{"key":"2019111616020841700_B37","doi-asserted-by":"crossref","first-page":"41950","DOI":"10.1038\/srep41950","article-title":"Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells","volume":"7","author":"Ma","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"2019111616020841700_B38","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1200\/JCO.2002.20.3.665","article-title":"Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia","volume":"20","author":"Gandhi","year":"2002","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111616020841700_B39","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3816\/CLML.2010.n.082","article-title":"A phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse","volume":"10","author":"Advani","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"2019111616020841700_B40","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1038\/sj.leu.2403097","article-title":"A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia","volume":"17","author":"Kolb","year":"2003","journal-title":"Leukemia"},{"issue":"2","key":"2019111616020841700_B41","first-page":"663","article-title":"Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia","volume":"9","author":"Rizzieri","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2019111616020841700_B42","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.2513","article-title":"Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792) [abstract]","volume":"34","author":"Plummer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111616020841700_B43","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2014-08-551499","article-title":"How I treat the older patient with acute myeloid leukemia","volume":"125","author":"Ossenkoppele","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2019111616020841700_B44","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1139\/o90-199","article-title":"Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis","volume":"68","author":"Wright","year":"1990","journal-title":"Biochem Cell Biol"},{"issue":"9","key":"2019111616020841700_B45","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.leukres.2007.01.004","article-title":"Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies","volume":"31","author":"Gojo","year":"2007","journal-title":"Leuk Res"},{"issue":"12","key":"2019111616020841700_B46","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0145-2126(03)00118-8","article-title":"Phase I and pharmacodynamic study of triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia","volume":"27","author":"Giles","year":"2003","journal-title":"Leuk Res"},{"issue":"3","key":"2019111616020841700_B47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10637-008-9115-6","article-title":"Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia","volume":"26","author":"Odenike","year":"2008","journal-title":"Invest New Drugs"},{"issue":"7","key":"2019111616020841700_B48","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.leukres.2005.12.013","article-title":"Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome","volume":"30","author":"Yee","year":"2006","journal-title":"Leuk Res"},{"issue":"1","key":"2019111616020841700_B49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.leukres.2007.05.003","article-title":"A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders","volume":"32","author":"Karp","year":"2008","journal-title":"Leuk Res"},{"issue":"4","key":"2019111616020841700_B50","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3324\/haematol.2013.097246","article-title":"A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms","volume":"99","author":"Zeidner","year":"2014","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/10\/1157\/879977\/advances015214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/10\/1157\/879977\/advances015214.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T13:57:01Z","timestamp":1751637421000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/10\/1157\/15874\/Inhibition-of-ATR-acutely-sensitizes-acute-myeloid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,22]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,5,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2017015214","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,22]]}}}